Screening of symptomatic women for ovarian cancer

The Lancet Oncology

Volumn 13, Issue 4, 2012, Pages

  Tone, Alicia A ^a   Huntsman, David G ^a   Miller, Dianne M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN;

AGE DISTRIBUTION; CANCER GRADING; CANCER SCREENING; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; EARLY DIAGNOSIS; FALSE POSITIVE RESULT; GENE MUTATION; HEALTH CARE SYSTEM; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; LETTER; OUTCOME ASSESSMENT; OVARY CANCER; PERITONEUM CANCER; PERSONALIZED MEDICINE; PRIORITY JOURNAL; UTERINE TUBE CARCINOMA; BLOOD; FEMALE; MASS SCREENING; METHODOLOGY; NOTE; OVARY TUMOR;

CA-125 ANTIGEN; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MASS SCREENING; OVARIAN NEOPLASMS;

EID: 84859134995     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70149-3     Document Type: Letter

References (10)

1. Gilbert L, Basso O, Sampalis J, et al. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project. Lancet Oncol 2012, 13:285-291.
2. Mehra K, Mehrad M, Ning G, et al. STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis. Front Biosci (Elite Ed) 2011, 3:625-634.
3. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009, 10:327-340.
4. Buys SS, Partridge E, Greene MH, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 2005, 193:1630-1639.
5. Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA 2011, 305:2295-2303. PLCO Project Team.
6. Hermsen BB, Olivier RI, Verheijen RH, et al. No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Br J Cancer 2007, 96:1335-1342.
7. Zhang S, Royer R, Li S, et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol 2011, 121:353-357.
8. Yemelyanova AV, Cosin JA, Bidus MA, Boice CR, Seidman JD Pathology of stage I versus stage III ovarian carcinoma with implications for pathogenesis and screening. Int J Gynecol Cancer 2008, 18:465-469.
9. Hartge P, Speyer JL Finding ovarian cancer. J Natl Cancer Inst 2012, 104:82-83.
10. Lim AW, Mesher D, Gentry-Maharaj A, et al. Predictive value of symptoms for ovarian cancer: comparison of symptoms reported by questionnaire, interview, and general practitioner notes. J Natl Cancer Inst 2012, 104:114-124.